1. Home
  2. MRCC vs LCTX Comparison

MRCC vs LCTX Comparison

Compare MRCC & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monroe Capital Corporation

MRCC

Monroe Capital Corporation

HOLD

Current Price

$6.52

Market Cap

141.3M

Sector

Finance

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.69

Market Cap

407.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRCC
LCTX
Founded
2011
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
141.3M
407.7M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
MRCC
LCTX
Price
$6.52
$1.69
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$8.00
$4.25
AVG Volume (30 Days)
89.6K
1.4M
Earning Date
11-05-2025
11-06-2025
Dividend Yield
11.04%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$43,742,000.00
$10,816,000.00
Revenue This Year
N/A
$5.24
Revenue Next Year
N/A
$126.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
24.05
52 Week Low
$5.86
$0.37
52 Week High
$8.85
$2.09

Technical Indicators

Market Signals
Indicator
MRCC
LCTX
Relative Strength Index (RSI) 48.98 46.72
Support Level $6.20 $1.65
Resistance Level $6.80 $1.82
Average True Range (ATR) 0.17 0.08
MACD 0.00 0.00
Stochastic Oscillator 52.54 48.00

Price Performance

Historical Comparison
MRCC
LCTX

About MRCC Monroe Capital Corporation

Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: